Plitidepsin

DCTPepD ID  DCTPepD0072

Active Ingredients   Plitidepsin

Description  A cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. Plitidepsin displays a broad spectrum of antitumor activities, inducing apoptosis by triggering mitochondrial cytochrome c release, initiating the Fas/DC95, JNK pathway and activating caspase 3 activation. This agent also inhibits elongation factor 1-a, thereby interfering with protein synthesis, and induces G1 arrest and G2 blockade, thereby inhibiting tumor cell growth.

Synonyms  APLD; Aplidin; Aplidine; DDB; Dehydrodemnin B; N-[1-(1,2-Dioxopropyl)-L-prolyl]didemnin A; Plitidepsin

Disease  Various forms of cancer

Classification

  

Peptide and derivative Cyclic Marine origin

Structure Information


Molecular Formula  C57H87N7O15

Molecular Weight  1110.3

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-N-[(2R)-1-[[(3S,6S,8S,12S,13R,16S,17R,20S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4-methyl-1-oxopentan-2-yl]-N-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide

InChI  InChI=1S/C57H87N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-34,36,39-44,46-47,49,66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1

InChI_Key UUSZLLQJYRSZIS-LXNNNBEUSA-N

SMILES  CC[C@@H]([C@H]1NC([C@H]([C@H](OC([C@@H](N(C([C@@H]2CCCN2C([C@@H](NC([C@H](C([C@@H](OC(C[C@@H]1O)=O)C(C)C)=O)C)=O)CC(C)C)=O)=O)C)CC3=CC=C(C=C3)OC)=O)C)NC([C@H](N(C([C@@H]4CCCN4C(C(C)=O)=O)=O)C)CC(C)C)=O)=O)C

External Codes


PubChem CID  9812534

DrugBank Accession Number  DB04977

NCI Thesaurus Code  C1689  

UNII  Y76ID234HW   GSRS

CAS  137219-37-5



Drug approval


Drug indication
    Intended for the treatment of various forms of cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT03070964 A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma Lymphoma Phase 2 Treatment
NCT02100657 Phase I Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Multiple Myeloma Phase 1 Other
NCT01102426 Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma Relapsed/Refractory Multiple Myeloma Phase 3 Treatment
NCT01876043 Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma Phase 2 Treatment
NCT00788099 Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas Advanced Solid Tumors; Lymphomas Phase 1 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.